Novel Coronavirus Information Center

Elsevier’s free health and medical research on novel coronavirus (2019-nCoV)

3D illustration of Coronavirus (? istock.com/Dr_Microbe)
3D illustration of Coronavirus (? istock.com/Dr_Microbe)

Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on Novel Coronavirus (also referred to as COVID-19 and its temporary title 2019-nCoV). All resources are free to access and include guidelines for clinicians and patients. Under the 'Research' tab you will find the latest early stage and peer-reviewed research from journals including The Lancet and Cell Press, as well as a link to the Coronavirus hub on ScienceDirect, where you will find every article relevant article to Coronavirus, SARS, and MERS freely available. Under the Clinical Solutions tab you will find resources for nurses, clinicians and patients, including FAQs on symptoms.


Introduction

Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier

Recent events have shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We will provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products, and a variety of other resources, like travel precautions from the CDC and media posts of interest to our community. We have also created a  interactive global map of experts based on Scopus data.

Read more

Expert guidance and commentary

6 of the most common coronavirus questions the media is asking

By Rodney E. Rohde, PhD | Feb 6, 2020

Rodney E Rohde, PhDAs an infectious disease and clinical microbiology expert, Prof. Rodney E. Rohde of the Texas State University College of Health Professions receives daily calls from the media, government and university officials, and public health and professional organizations asking him about the emerging novel coronavirus outbreak. In this article, he shares some of the most common questions and his responses. Read more.

Prof. Rohde has also published two nCoV articles with the American Society for Microbiology (ASM):


Interactive map: global disease outbreak experts

The map represents the most active institutions researching disease outbreak and control. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications researching the coronavirus and related diseases such as SARS from 1996 to the present (Feb 6, 2020). We then used the resulting ~22,000 publications to identify the researchers and institutions that are working in these areas. The map shows the 500 most prolific global institutions, along with the 200 most prolific Chinese institutions by publication count.

Click on a pin to see more about the institution, the numbers of researchers and their publications. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

Legend

Video: Novel Coronavirus Update

Livestreamed on Feb 6, 2020

JAMA Editor-in-Chief Howard Baucher, MD, interviews Anthony Fauci, MD, Director of the NIH National Institute of Allergy and Infectious Diseases.



Key facts for clinicians

By Margaret Trexler Hessen, MD | Updated Feb 3, 2020

Background: In December, China notified the World Health Organization of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, now called 2019-nCoV. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Cases have now been reported in many part of mainland China and in other countries in Asia, Europe, the eastern Mediterranean, Australia, Asia Pacific and North America. Travel within China has been restricted  travel to and from China markedly reduced. Screening of travelers is being implemented in other countries and quarantine measures have been enacted under some circumstances. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally.

Novel coronaviruses have emerged as human pathogens in the past, notably associated with outbreaks of SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Current investigative methods and recommendations derive in some part from the experience of those epidemics.

Clinical presentation: The incubation period is thought to be 2 to 14 days. Symptoms include fever (which may be absent in persons at extremes of age or with immunocompromise), cough and dyspnea. Chest radiographs may show bilateral infiltrates. Clinical illness varies from mild to severe; about 25% of confirmed cases have been classified as severe, and there are increasing numbers of deaths. In early cases, mortality was associated with advanced age or comorbidities.

Diagnosis: Although respiratory infections (including influenza) are prevalent in the northern hemisphere during the winter, clinicians should inquire about travel history in persons presenting with respiratory illness. The possibility of 2019-nCoV infection should be suspected in persons who present with compatible clinical illness and exposure history. The US Centers for Disease Control (CDC) and World Health Organization (WHO) have slightly different criteria for whom to test, as noted below:

  • Recent travel (within 14 days) from Wuhan, Hubei Province, China (WHO). The CDC has broadened geographic criteria to include travel from Hubei Province — and for persons with fever and lower respiratory illness requiring hospitalization, travel from mainland China.
  • Close contact with a person suspected or known to have infection due to 2019-nCoV (WHO, CDC). The CDC defines close contact as being within 6 feet (2 meters) or within a room or care area for a prolonged period without personal protective equipment OR having direct contact with secretions of a person with 2019-nCoV infection.
  • Exposure to a healthcare facility in a country where hospital-associated nCoV infections have been reported (WHO).
  • The disease occurs in a healthcare worker who has been working in an environment where patients with severe acute respiratory infections are being cared for, without regard to place of residence or history of travel (WHO).
  • The person develops an unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment, without regard to place of residence or history of travel, even if another etiology has been identified that fully explains the clinical presentation (WHO).
  • In Hubei province only, a trained medical professional can now classify a suspected case of COVID19 as a clinically-confirmed case on the basis of chest imaging, rather than a laboratory confirmation (WHO, as of 13 Feb 2020)

In the United States, suspected cases should be reported immediately to local or state health departments, which will determine whether the patient meets clinical and epidemiologic criteria for disease and coordinate diagnostic testing of suspected patients through the CDC. Collection of specimens from the upper respiratory tract, lower respiratory tract and serum is recommended as a priority; other specimens, such as stool or urine, may be collected and stored to be tested at the discretion of the CDC. The CDC provides detailed information on collection and shipping of specimens for cases approved by local or state authorities. The CDC advises that testing for other respiratory pathogens by the provider should be done as part of the initial evaluation and should not delay specimen shipping to CDC.

If a patient with suspected 2019-nCoV infection tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a person under investigation.

Management: No specific antiviral agent is available for treatment of this infection, and there is no vaccine. Treatment is supportive and includes supplemental oxygen and conservative fluid management, as indicated by clinical condition. WHO provides detailed guidance on such supportive measures and cautions that severely ill patients should be treated empirically for other possible causes while diagnostic test results are pending.

Infection control measures are an integral part of management:

  • Provide the patient with a face mask and place the patient in a closed room (preferably with structural safeguards against airborne transmission).
  • Persons entering the room should follow standard, contact, and airborne precautions.
  • Patients managed at home are encouraged to self-isolate to a single area of the house (preferably with a separate bathroom) and to wear a face mask during any contact with household members.
  • The patient and all household members should follow diligent hand and cough hygiene.

Complications: Respiratory failure and septic shock occur in some patients. The case fatality rate is about 2 percent.

Margaret Trexler Hessen, MD, is an infectious disease specialist with 20 years of clinical practice experience and public health service, including outbreak management. She has been with Elsevier since 2010 and is currently Director, Point of Care.



Clinicians need reliable and current information to combat novel coronavirus

By Jonathan Temte, MD, PhD | January 27, 2020

Jonathan Temte, MD, PhD, Consultant, PracticeUpdate, ElsevierCoronaviruses are incredibly diverse, found in many animal species, and are commonly encountered in clinical practice during the cold and flu season, yet many primary care clinicians are not familiar with these respiratory pathogens. We rarely test for them, and when we do it’s usually when we’re looking for something else. Moreover, we have no specific treatments for these viruses.

The usual suspects have funny names: coronavirus HKU1, NL63, 229E and OC43. In our ongoing surveillance and epidemiological studies in school, clinics and longterm care settings, we find all four of these. There are two other coronaviruses that have been previously shown to infect humans: SARS (severe acute respiratory syndrome-associated coronavirus, or SARS-CoV), which emerged in 2003, and MERS (Middle East Respiratory Syndrome Coronavirus, or MERS-CoV), which emerged in 2012. SARS and MERS are associated with high case fatality rates.

Now a novel coronavirus, named 2019-nCoV, has emerged in China. There are hundreds of cases in China and multiple cases across the globe. The second case in the US was confirmed Friday in Illinois. We are extremely early in this rapidly expanding outbreak. With this evolving situation comes fear, misinformation and many unknowns. Accordingly, clinicians need to find reliable and current sources of credible information. A good place to start is the CDC resource page for healthcare professionals.

Jonathan Temte, MD, PhD, is Associate Dean for Public Health and Community Engagement and Professor of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health and former Chair of the Advisory Committee on Immunization Practices (ACIP). Jon currently serves as Chair of the Wisconsin Council on Immunization Practices and has been active on pandemic influenza and bioterrorism working groups for the state. He is a consultant for Elsevier's PracticeUpdate.


Elsevier Clinical Solutions

We've selected content from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education collections to share what we know to date about the novel coronavirus.

Clinical Overviews on ClinicalKey

Clinical Overviews are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops Clinical Overviews through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.

Clinical Skills for Nursing

Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:

Interprofessional Care Plans

These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.

Patient engagement resources

Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:


Video overview of Coronavirus from 3D4Medical - Watch now:


中文資源 (Chinese-language resources)

TitlePublished by (CN)Published by (EN)Link
Virology 
2019新型冠狀病毒信息庫   National Genomics Data Center

https://bigd.big.ac.cn/ncov

新型冠狀病毒國家科技資源服務系統。共享:
1)第一株病毒毒種信息及其電鏡照片
2)新型冠狀病毒核酸檢測引物和探針序列
國家微生物科學數據中心和國家病原微生物資源庫 National Microbiological Data Center;
National Pathogen Resource Collection Center
http://nmdc.cn/#/nCoV
Diagnosis & Treatment Guidelines
新型冠狀病毒感染的肺炎診療方案(試行第三版)(PDF可下載) 國家衛生健康委員會 National Health Commission http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml
湖北省新型冠狀病毒感染的肺炎診療方案(試行第一版) 湖北省醫療救治專家組 Medical Expert Panel of Hubei Province https://xw.qq.com/cmsid/20200123A0KNOW00
《新型冠狀病毒肺炎診療快速指南》 華中科技大學同濟醫學院附屬同濟醫院專家組 Tongji Hospital, Tongji Medical College of HUST https://xw.qq.com/health/20200124010910/HLH2020012401091000
《武漢協和醫院處置2019新型冠狀病毒感染策略及說明》 華中科技大學同濟醫學院附屬協和醫院專家組 Xiehe Hospital, Tongji Medical College of HUST https://www.dxy.cn/bbs/newweb/pc/post/42662254
關于“新型冠狀病毒感染的肺炎”診療建議方案(V2.0)中國醫學科學院北京協和醫院Peking Union Medical College Hospital, CAMShttps://new.qq.com/omn/HLH20200/HLH2020012501009300.html
醫療機構內新型冠狀病毒感染預防與控制技術指南(第一版)國家衛生健康委員會National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml

新型冠狀病毒實驗室生物安全指南(第二版)國家衛生健康委員會National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml

新型冠狀病毒感染的肺炎診療方案(試行第四版)國家衛生健康委員會National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67.shtml

新型冠狀病毒感染的肺炎防控方案(第三版)國家衛生健康委員會National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128513fe46f086d79667db9f76a5.shtml

新型冠狀病毒感染的肺炎病例轉運工作方案(試行)國家衛生健康委員會National Health Commissionhttp://www.nhc.gov.cn/xcs/zhengcwj/202001/ccee6ec0942a42a18df8e5ce6329b6f5.shtml
新型冠狀病毒感染的肺炎患者遺體處置工作指引(試行)國家衛生健康委員會National Health Commissionhttp://www.nhc.gov.cn/yzygj/s7659/202002/163c26a24057489dbf64dba359c59a5f.shtml
Epidemic situation
 新型冠狀病毒感染的肺炎疫情分布 中國疾病預防控制中心 Chinese Center for Disease Control and Prevention

http://2019ncov.chinacdc.cn/2019-nCoV

    
Research articles and book chapters
Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22] 中國疾病預防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57 
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21] 中國疾病預防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c
中國新型冠狀病毒感染病例首批臨床數據報告(解讀, The Lancet  Weichat Official Account The Lancet Weichat Official Account https://marlin-prod.literatumonline.com/pb-assets/Lancet/marketing/wechat/WeChat_website.jpg
引自《默里及納達爾呼吸醫學》,V Courtney Broaddus 主編,李為民、程德云主譯,人民衛生出版社,2018 李為民、程德云主譯,人民衛生出版社,2018 Elsevier, with content quoted from translation published by PMPH

Influenza

Pneumonia

Coronavirus

Patient Education
輕癥疑似2019新型冠狀病毒患者及密切接觸人員如何進行自我管理 北京協和醫院呼吸科 Respiratory Department, Peking Union Medical College Hospital, CAMS http://m.sohu.com/a/368777653_102327
《新型冠狀病毒感染防護》   Elsevier Clinical Solutions 新型冠狀病毒感染防護》
Institutional Special Reports
國家衛生健康委員會新型冠狀病毒感染的肺炎專題 國家衛生健康委員會 National Health Commission http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
中國疾病預防控制中心新型冠狀病毒感染的肺炎專題 中國疾病預防控制中心 Chinese Center for Disease Control and Prevention http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/
中國疾病預防控制中心周報(English Version) 中國疾病預防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/
丁香園丁香熱點 丁香園 DingXiangYuan https://www.dxy.cn/bbs/newweb/pc/board/151/3484
疫情地圖及趨勢圖丁香園DingXiangYuanhttps://3g.dxy.cn/newh5/view/pneumonia
Key Media Special Reports
抗擊肺炎專題 今日頭條 Beijing Byte Dance Technology Co., Ltd. https://www.toutiao.com/
#我在疫情第一線# 三聯生活周刊 Sanlian Life Weekly https://s.weibo.com/weibo?q=%23%E6%88%91%E5%9C%A8%E7%96%AB%E6%83%85%E4%B8%80%E7%BA%BF%23&from=default

Video overview (Chinese language voice over)

全球冠狀病毒研究機構及研究人員分布圖

基于愛思唯爾獨有的全球最大的引文摘要數據庫Scopus,聚焦冠狀病毒疫情爆發及疫情控制研究。通過關鍵詞檢索分析,得到了自1996年至今已發表的22000多篇文獻。在科研表現世界地圖中,展示了全球表現突出的500多所科研機構(發文量超過10篇含)。其中,中國的科研機構有200多所。在這200多所中國科研機構中,中國大陸有150所,中國香港有15所,中國臺灣有43所。

中國的科研機構按照發文量來看,香港大學以2888篇占據首位,遠遠高于排在第二位的香港中文大學(1766篇),中國農科院以1519篇論文緊隨其后。其他占據發文前十的科研機構還包括中國醫學科學院、國立臺灣大學、中科院微生物所、中國疾病預防控制中心、北京大學、華中農業大學和首都醫科大學。除此之外,復旦大學、中國軍事醫學科學院、清華大學、華南農業大學、中山大學、中科院武漢病毒所也分別發表了超過400篇的相關科研論文。

通過互動地圖,不僅可以概覽全球特別是中國的相關研究機構分布,同時還可以通過放大或縮小地圖來聚焦某個研究機構,靶定該機構的研究人員來進行深入分析,以獲取更多有價值的信息。

注:按照發文量進行排名,地圖中藍色標記的為全球冠狀病毒研究排名前500的機構,紅色標記為中國排名前200的機構,紫色標記為排在全球前500機構中的中國機構。

Because Google is not available in China and various other countries, we are offering a local version of the map, enabling you also to download the data.

View the interactive version on Baidu


Research

In this section, you can find the following resources:

The Lancet Coronavirus hub

View this infographic and other coronavirus content on The Lancet's Coronavirus hub.

To assist health workers and researchers working under difficult and dangerous conditions to bring this outbreak to a close, The Lancet has created a Coronavirus hub page. This hub brings together new coronavirus content from The Lancet journals as it is published.

You can also find related information from Cell Press here

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | Chongqing VIP Information

Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.


Articles in Elsevier journals

Below are a selection of articles curated by our clinical solutions team and directly relevant to Novel Coronavirus (2019-nCov).

In addition to these, Elsevier has made more than 2,500 coronavirus-related articles freely available for the next six months (commencing 10/02/2019). You can find these articles here.

We will be updating this section continually.

More published research

Book chapters


Early-stage research (preprints on SSRN platform)

Emerging and rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.

SSRN, Elsevier’s world-leading platform devoted to the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.


Resources for drug discovery

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we will use those tools to generate information relevant to combatting 2019-nCoV.


Download this and other infographics for the public from the WHO novel coronavirus website.  Download this and other infographics from the WHO's website Novel Coronavirus advice for the public.Here, you will find official guidance from major health organizations such as the CDC and WHO and media posts of interest to our community.

Official coronavirus guidance from various countries:

Argentina | Australia | Canada | Chile | China | Colombia | France | Germany | Mexico | Peru | Singapore | Spain | UK | US

In the media


Contributors


Written by

Elsevier Connect

Written by

Elsevier Connect

This site features daily stories for the global science, health and technology communities, written by experts in the field as well as Elsevier colleagues.